---
document_datetime: 2025-12-04 08:58:54
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sunitinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sunitinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7048474
conversion_datetime: 2025-12-20 18:09:42.813964
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sunitinib Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Renewal - 5 year /   | - Renewal - | 18/09/2025                          | 26/11/2025                                  | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/R/0000269316                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                                                                                                                                                                                                                                        |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000262701 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.4 and 4.8 of the SmPC and section 4 of the PL with information on hyperammonaemic encephalopathy in line with the product information of the reference product, Sutent, following the assessment of the same changes in procedure EMEA/H/C/PSUSA/00002833/202304. Additionally, the MAH has taken the opportunity to update sections 4.6 and 5.2 of the SmPC with editorial changes to align with the reference product information. | 06/05/2025 | 26/11/2025 | SmPC and PL | To update sections 4.4 and 4.8 of the SmPC and section 4 of the PL with information on hyperammonaemic encephalopathy in line with the product information of the reference product, Sutent, following the assessment of the same changes in procedure EMEA/H/C/PSUSA/00002833/202304. |
| Variation type IB / EMA/VR/0000245963 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minor change to the restricted part of an Active Substance Master File - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/02/2025 | N/A        |             |                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                        | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted   |            |            |    |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| EMEA/H/C/005419/N/0003 | Update of the Package Leaflet to include the list of local representatives.                                                                                  | 12/04/2024 | 29/05/2024 | PL |